Zenotech Lab. Q1 FY27 Results (BSE: 532039)
Signal: Slipped to loss
The read
Zenotech's Q1FY27 standalone results show a sharp reversal: revenue grew 11% YoY to ₹9.60 Cr, but employee costs (+39% YoY) and other expenses (+33% YoY) surged far faster, driving an operating loss of ₹0.60 Cr vs a ₹1.28 Cr profit a year ago. The net loss of ₹0.46 Cr was cushioned by a ₹2.39 Cr prior-period tax credit and a deferred tax credit of ₹0.15 Cr; without these, the bottom-line loss would have exceeded ₹3 Cr. This is the second consecutive quarterly operating loss (Q4FY26 EBITDA was also negative), suggesting a structural cost problem rather than a one-off. The company's reliance on biotech facility rental income (₹1.02 Cr other operating income, flat YoY) provides a base but cannot absorb the fixed-cost escalation. No consolidated results are filed as subsidiaries are defunct/wound up, so the standalone picture is the whole story.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹9.6 Cr | 11.1% | 8.2% |
| EBIT | ₹-0.6 Cr | -147.0% | |
| Net profit | ₹-0.46 Cr | -146.0% | |
| EPS | ₹-0.07 | -143.8% | |
| EBIT margin | -6.3% |
P&L walk
Revenue grew modestly (+11.1% YoY, +8.2% QoQ) but costs surged far faster — employee costs +39.0% YoY and other expenses +32.5% YoY — flipping the EBITDA from +₹1.28 Cr profit in Q1FY26 to -₹0.60 Cr loss in Q1FY27; a prior-period tax credit of ₹2.39 Cr only partially offset the operating loss, resulting in net loss of ₹0.46 Cr vs. ₹0.99 Cr profit a year ago. This is the second consecutive quarter of operating loss.
Key positives
- Revenue grew 11.1% YoY and 8.2% QoQ to ₹9.60 Cr, showing some demand traction in pharma operations and stable rental income.
Key concerns
- Employee costs surged 39.0% YoY to 51.2% of revenue (vs 40.9% a year ago), the primary driver of operating loss.
- Other expenses rose 32.5% YoY to 50.3% of revenue (vs 42.2% a year ago), compounding margin pressure.
- Operating EBITDA turned negative for the second consecutive quarter (-₹0.60 Cr vs +₹1.28 Cr a year ago), indicating a structural cost issue.
- Net profit swung from +₹0.99 Cr to -₹0.46 Cr YoY; the loss would have been deeper without ₹2.54 Cr in tax credits.
Research and educational content only. Not investment advice.